NEW PATHOGENETIC FACTORS OF ATHEROSCLEROSIS DEVELOPMENT AND POTENTIAL THERAPEUTIC APPROACHES
| Autor: | I. Ya. Kalvinsh |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 12, Iss 5, Pp 87-90 (2013) |
| Druh dokumentu: | article |
| ISSN: | 1728-8800 2619-0125 |
| DOI: | 10.15829/1728-8800-2013-5-87-90 |
| Popis: | It has been demonstrated that one of the factors in the pathogenesis of atherosclerosis, with the subsequent development of myocardial infarction (MI), stroke (S), or sudden death (SD), is trimethylaminoxide (TMAO), the end-product of dietary choline, betaine, or carnitine metabolism by intestinal microflora. Simultaneously elevated levels of TMAO and carnitine are associated with a doubled or even tripled risk of MI, S, and SD. Therefore, dietary intake of choline-rich phosphatidylcholine fats and red meats and carnitine-rich dairy is an important risk factor (RF) of atherosclerosis. At the moment, there is no universally accepted therapeutic approach which reduces TMAO and carnitine levels. The only agent which can simultaneously reduce the levels of these two atherosclerosis-associated RFs is a well-known cardio- and cytoprotector Mildronate. Experimental and pilot clinical studies of Mildronate effectiveness in patients with obliterating atherosclerosis suggest the need for further, more detailed clinical trials of Mildronate, for estimation of its efficacy and safety. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|